InspireMD

InspireMD is a medical device company developing and commercialising stent and neuroprotection systems for carotid artery disease. Its core technology is MicroNet, a biocompatible polymer mesh wrapped around a stent to trap plaque debris and prevent embolisation during carotid stenting; the mesh platform underpins the CGuard carotid embolic prevention system and the newer CGuard Prime stent. The company's SwitchGuard neuroprotection system delivers flow-reversal cerebral protection during transcarotid artery revascularisation (TCAR) and is being evaluated in the CGUARDIANS III pivotal study. InspireMD voluntarily recalled its CGuard Prime 135 cm delivery system in the United States in May 2026 after technical success fell short of expectations during a controlled launch, withdrew its 2026 revenue guidance and is pursuing design changes ahead of a new FDA submission, while it awaits FDA decisions on the CGuard Prime 80 cm implant for TCAR and the original CGuard platform. The company was founded in 2005, is headquartered in Miami, Florida, employs roughly 127 people and has been listed on Nasdaq since 2011.